KR970032871A - 피부염의 치료외용제 - Google Patents

피부염의 치료외용제 Download PDF

Info

Publication number
KR970032871A
KR970032871A KR1019960020250A KR19960020250A KR970032871A KR 970032871 A KR970032871 A KR 970032871A KR 1019960020250 A KR1019960020250 A KR 1019960020250A KR 19960020250 A KR19960020250 A KR 19960020250A KR 970032871 A KR970032871 A KR 970032871A
Authority
KR
South Korea
Prior art keywords
dermatitis
aqueous solution
external preparation
cyclodextrin
clathrate
Prior art date
Application number
KR1019960020250A
Other languages
English (en)
Other versions
KR0181763B1 (ko
Inventor
하지메 야마다
아키라 야마다
Original Assignee
야마다 미츠요
가부시키가이샤 시에시
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 야마다 미츠요, 가부시키가이샤 시에시 filed Critical 야마다 미츠요
Publication of KR970032871A publication Critical patent/KR970032871A/ko
Application granted granted Critical
Publication of KR0181763B1 publication Critical patent/KR0181763B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Carriers, Traveling Bodies, And Overhead Traveling Cranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

부신피질 스테로이드를 사이클로덱스트린으로 포접하여, 다당류를 함유하는 수용액중에 용해한다. 부신피질 스테로이드를 0.025∼0.5중량%, 사이클로덱스트린을 0.2∼30중량%, 다당류를 0.5∼55중량%로 한다. 다당류는 덱스트란 또는 풀롤란등을 사용한다. 수용액중에는 포도당, 무탄, 렌티난, 염화나트륨, 염화칼슘, 염화칼륨을 첨가한다.
아토피성 피부염 등을 완치할 수 있고, 게다가 부작용의 우려가 없어 매우 높은 안전성을 갖는다.

Description

피부염의 치료외용제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 부신피질 스테로이드를 사이클로덱스트린으로 포접하고, 다당류를 함유하는 수용액 중에 용해하는 것을 특징으로 하는 피부염의 치료외용제.
  2. 제 1항에 있어서, 부신피질 스테로이드를 0.025∼0.5중량%, 사이클로덱스트린을 0.01∼30중량%, 다당류를 0.5∼5.5중량%로 하는 것을 특징으로 하는 피부염의 치료외용제.
  3. 제 1항 또는 제 2항에 있어서, 다당류는 덱스트란 또는 플룰란등을 사용하는 것을 특징으로 하는 피부염의 치료외용제.
  4. 제 1항 내지 제 3항의 어느 한항에 있어서, 수용액의 성분은 포도당, 무탄, 렌티난, 염화나트륨, 염화칼슘, 염화칼륨을 첨가하는 것을 특징으로 하는 피부염의 치료외용제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960020250A 1995-12-11 1996-06-07 피부염의 치료외용제 KR0181763B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP95-346006 1995-12-11
JP7346006A JP2920611B2 (ja) 1995-12-11 1995-12-11 皮膚炎の治療外用剤

Publications (2)

Publication Number Publication Date
KR970032871A true KR970032871A (ko) 1997-07-22
KR0181763B1 KR0181763B1 (ko) 1999-05-01

Family

ID=18380498

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960020250A KR0181763B1 (ko) 1995-12-11 1996-06-07 피부염의 치료외용제

Country Status (14)

Country Link
US (1) US5885978A (ko)
EP (1) EP0780129B1 (ko)
JP (1) JP2920611B2 (ko)
KR (1) KR0181763B1 (ko)
CN (1) CN1153571C (ko)
AT (1) ATE290883T1 (ko)
AU (1) AU705996B2 (ko)
CA (1) CA2173403C (ko)
DE (1) DE69634472T2 (ko)
DK (1) DK0780129T3 (ko)
ES (1) ES2240987T3 (ko)
HK (1) HK1004979A1 (ko)
SG (1) SG48460A1 (ko)
TW (1) TW431889B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
IT1319665B1 (it) * 2000-11-17 2003-10-23 Pharma Biotech Ltd Addotti di corticosteroidi con polimeri polisaccaridici naturali.
EP1216712A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
ATE446096T1 (de) 2002-06-03 2009-11-15 Cac Corp Topische präparate zur behandlung von dermatitis
FR2842106B1 (fr) * 2002-07-11 2006-07-14 Centre Nat Rech Scient Dispersions aqueuses de particules nanometriques ou micrometriques pour l'encapsulation de composes chimiques
KR100564153B1 (ko) * 2002-11-28 2006-03-27 주식회사 에이치 엔 비티 아토피성 피부염을 개선시키는 조성물
WO2005120578A2 (en) * 2004-06-07 2005-12-22 California Institute Of Technology Biodegradable drug-polymer delivery system
WO2005121328A2 (en) * 2004-06-11 2005-12-22 Syngenta Limited Method for ameliorating an inflammatory skin condition
JP5456802B2 (ja) * 2012-01-23 2014-04-02 株式会社Ｃａｃ 細胞遊走促進剤及び創傷治療用の経皮吸収剤
JP6313118B2 (ja) * 2014-05-16 2018-04-18 株式会社Cac ＩｇＥ抑制剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5231019B2 (ko) * 1973-10-16 1977-08-12
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPS61246130A (ja) * 1985-04-24 1986-11-01 Japan Fine Chem Kk 水性皮膚及び毛髪化粧料
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
ES2037385T3 (es) * 1988-01-14 1993-06-16 Akzo N.V. Un procedimiento de manufactura de una preparacion farmaceutica para administracion local.
US5019562A (en) * 1988-01-19 1991-05-28 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Growth inhibiting agent and the use thereof
JPH0795311B2 (ja) * 1988-06-30 1995-10-11 日本電気株式会社 二重化処理装置
US5229370A (en) * 1988-08-15 1993-07-20 Ammeraal Robert N Water soluble branched beta cyclodextrin steroid complex
JP2681527B2 (ja) * 1990-02-15 1997-11-26 ジャパンファインケミカル株式会社 細胞活性促進外用剤
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
JP2578048B2 (ja) * 1992-05-22 1997-02-05 株式会社 シーエーシー 循環瀘過装置
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
JP3535883B2 (ja) * 1993-06-25 2004-06-07 井関農機株式会社 作業機連結装置
JPH0756417A (ja) * 1993-08-09 1995-03-03 Ricoh Co Ltd 回転型現像装置
JP2772619B2 (ja) * 1994-06-28 1998-07-02 株式会社シーエーシー 多糖類水溶液用循環風呂

Also Published As

Publication number Publication date
ES2240987T3 (es) 2005-10-16
EP0780129B1 (en) 2005-03-16
DK0780129T3 (da) 2005-06-20
CA2173403C (en) 2000-05-16
AU5056096A (en) 1997-06-19
JPH09157171A (ja) 1997-06-17
CA2173403A1 (en) 1997-06-12
KR0181763B1 (ko) 1999-05-01
DE69634472T2 (de) 2006-02-16
CN1151866A (zh) 1997-06-18
EP0780129A2 (en) 1997-06-25
SG48460A1 (en) 1998-04-17
JP2920611B2 (ja) 1999-07-19
ATE290883T1 (de) 2005-04-15
EP0780129A3 (en) 2000-07-19
DE69634472D1 (de) 2005-04-21
CN1153571C (zh) 2004-06-16
HK1004979A1 (en) 1998-12-18
AU705996B2 (en) 1999-06-03
US5885978A (en) 1999-03-23
TW431889B (en) 2001-05-01

Similar Documents

Publication Publication Date Title
Kjellén et al. Binding of heparin and heparan sulphate to rat liver cells
DE69231935T2 (de) Konjugat enthaltend ein geradkettiges organisches polymer mit gebundenen sulfatierten glukosaminoglukanen wie zum beispiel heparin, seine herstellung, verwendung und ein entsprechendes substrat
KR970032871A (ko) 피부염의 치료외용제
AU692389B2 (en) Cyclodextrin compounds and methods of making and use thereof
ATE35418T1 (de) Oligosaccharide mit selektiver, antikoagulierender wirkung.
US3247063A (en) Anticoagulants containing heparin and polysaccharides
CA2209696A1 (fr) Utilisation d'un polyholoside dans une composition destinee a stimuler les defenses immunitaires, et composition le comprenant
BR9808008A (pt) Processo para o tratamento anticoagulante e/ou antitrombótico de um ser humano ou outro paciente animal de sangue quente, usos de um oligossacarìdeo sulfatado e na fabricação de um medicamento, e, composição farmacêutica ou veterinária para tratamento anticoagulante e/ou antitrombótico.
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
KR100647857B1 (ko) 피부염 치료용 외용제
RU2216548C2 (ru) Смесь линейных олигосахаридов, полученная из дерматансульфата, фармацевтическая композиция, обладающая антитромботическим действием, и способ лечения
Coppa et al. Urinary excretion of disulfated disaccharides in Hunter syndrome: Correction by infusion of a serum fraction
Davies et al. The influence of propranolol on the thyrotropin receptor
JP2005220347A (ja) 局所的送達の治療用抗血栓剤として有用なトリエタノールアミンを伴う低分子量ヘパリン塩、それらの調製方法、ヘパリン塩の吸湿性を除去するためのプロセス、抗血栓療法における局所的使用のための薬学組成物及びそれにおける使用
HUP9901784A2 (hu) Eljárás keményítő oxidálására
BR0202439A (pt) Complexo, método para prolongar o tempo que o ocif ou um seu análogo ou variante fica retido na corrente sang ìnea, composição farmacêutica, uso de um complexo, e, método para a preparação de um complexo
KR930019219A (ko) 만성 피로 증후군 치료제
Grant et al. Chemical changes in rabbit aorta and ear cartilage induced by papain and calciferol
FI57209C (fi) Foerfarande foer stabilisering av en suspension av bariumsulfat i vatten
JPH06279292A (ja) 生理活性を有するグリコーゲンの製法及び生理活性
Ellis Effect of Diisopropyl Fluorophosphate (DFP) on the Q02 of the Rabbit Cerebral Cortex
Widyasari et al. Labeled of Irradiated Chitosan with IODIUM-131 Radioisotope
KR890004710A (ko) 상처의 치유 촉진을 위한 합성 황산 사카라이드의 용도
KR860000073A (ko) 기계적 응력에 대해 안정화된 수성인슐린 제제의 제조방법
Violand et al. Permeabilization of Ehrlich ascites tumor cells by human serum

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130924

Year of fee payment: 16

FPAY Annual fee payment

Payment date: 20141006

Year of fee payment: 17

FPAY Annual fee payment

Payment date: 20151027

Year of fee payment: 18

EXPY Expiration of term